CARL
Get informed when a big investor buys or sells
+ Follow| Market cap | $310.45 Million |
|---|---|
| Enterprise Value | $254.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.12 |
| Beta | 1.39 |
| Outstanding Shares | 26,835,841 |
| P/E Ratio | -9.24 |
|---|---|
| PEG | -17.83 |
| Price to Sales | 5.57 |
| Price to Book Ratio | 3.71 |
| Enterprise Value to Revenue | 4.51 |
| Enterprise Value to EBIT | -6.69 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.19 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 37.28%▲ 15.11% |
|---|---|
| Total Invested | $48.00M▼ 16.83% |
| Investors Holding | 66▲ 9.00% |
No data
Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. Its product ...